Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy

• Verfasst von: Aulmann, Sebastian [VerfasserIn]
• Verfasst von: Waldburger, Nina [VerfasserIn]
• Verfasst von: Penzel, Roland [VerfasserIn]
• Verfasst von: Andrulis, Mindaugas [VerfasserIn]
• Verfasst von: Schirmacher, Peter [VerfasserIn]
• Verfasst von: Sinn, Peter [VerfasserIn]
• Titel: Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy
• Verf.angabe: Sebastian Aulmann, Nina Waldburger, Roland Penzel, Mindaugas Andrulis, Peter Schirmacher, Hans Peter Sinn
• Jahr: 2010
• Umfang: 8 S.
• Fussnoten: Online verfügbar 11 Dezember 2009 ; Im Titel sind die Zeichen + und - hochgestellt ; Gesehen am 28.11.2022
• Titel Quelle: Enthalten in: Human pathology
• Ort Quelle: New York, NY [u.a.] : Elsevier, 1970
• Jahr Quelle: 2010
• Band/Heft Quelle: 41(2010), 4, Seite 574-581
• ISSN Quelle: 1532-8392
• DOI: doi:10.1016/j.humpath.2009.08.023
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Breast cancer
• Sach-SW: CD24
• Sach-SW: CD44
• Sach-SW: Stem cells
• K10plus-PPN: 1823725376

Abstract

Breast cancer cells with the CD44+/CD24− phenotype have been associated with stem cell properties. To analyze effects of cytotoxic chemotherapy on these cells, we examined a series of 50 breast carcinomas before and after neoadjuvant chemotherapy with epirubicin/cyclophosphamide using double immunofluorescence. Before treatment, an average of 4.4% of the tumor cells displayed a CD44+/CD24− phenotype. However, after chemotherapy, the frequency of CD44+/CD24− cells dropped to 2% (P = .008). To test this unexpected finding, we analyzed a second collective of 16 patients that preoperatively had received either 4 cycles of doxorubicin/pemetrexed, followed by 4 cycles of docetaxel or 4 cycles of doxorubicin/cyclophosphamide, followed by 4 cycles of docetaxel with similar results (8.7% CD44+/CD24− cells on average before and 1.1% after chemotherapy). In addition, no association was observed between the frequency of CD44+/CD24− cells and the response to chemotherapy or patient survival. However, patients with tumors containing high numbers of CD44+/CD24− cells more frequently developed bone metastases in the course of disease. In conclusion, our findings challenge the proposed role of CD44+/CD24− cells as cancer stem cells in tumor resistance to chemotherapy as they apparently are not selected by conventional cytotoxic agents.